Login to Access Video or Poster Abstract: MP93-15
Sources of Funding: The Prostate Cancer Guys Resilient by Individualized Training (PCaGRIT) trial was supported the University of Kansas Cancer Center Cancer Prevention Pilot Grant program (JHR), and in part by an NIH Clinical and Translational Science Award grant (UL1 TR000001, formerly UL1RR033179), awarded to the University of Kansas Medical Center. Support for J. Hamilton-Reeves was provided by KL2 training grant KL2TR000119 a CTSA grant from NCATS awarded to the University of Kansas Medical Center for Frontiers: The Heartland Institute for Clinical and Translational Research (JHR). The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH or NCATS. Research reported in this publication was supported by the National Cancer Institute Cancer Center Support Grant P30 CA168524 and used the Biospecimen Shared Resource and the Biostatistics and Informatics Shared Resource. Medifast donated the meal replacements for the study.

Introduction

Men who are overweight at the time of prostatectomy are more likely to have recurrence and die from prostate cancer than healthy weight men. They also have higher risk for cardiovascular disease, the most common cause of death for prostate cancer survivors. Our study tests the feasibility of weight loss before and maintenance after prostatectomy in overweight men with localized prostate cancer.

Methods

Men scheduled for prostatectomy received a weight management program (intervention; n=15) or standard of care (non-intervention; n=5). The intervention included behavior coaching, diet including meal replacements, physical activity, and self-monitoring technology. Body weight, body composition, cardiometabolic markers, and quality of life were measured at baseline, 1 week before surgery, and 12 weeks after surgery. Changes within and differences between groups were analyzed using the two-sample t-test.

Results

The intervention led to 6 kg of weight loss (95%CI, 3-8 kg; P<0.001) and 4 kg of fat loss (95%CI, 2-6 kg; P<0.001) from baseline to surgery (mean=6.6 weeks). Between group differences in weight change and fat loss were significant (P=0.012; P=0.032, respectively). In the intervention group, blood glucose decreased by 11 mg/dL (95%CI, 0.5-22 mg/dL; P=0.04); insulin decreased by 3.4 µIU/mL (95%CI, 0.1-7 µIU/mL; P=0.03); C-peptide decreased by 0.7 ng/L (95%CI, 0.17-1.3 ng/L; P=0.01); systolic blood pressure decreased by 8 mmHg (95%CI, 1-15 mmHg; P=0.03); and leptin:adiponectin ratio decreased (P=0.008) from baseline to surgery. Changes in lipid profiles were not significant. Twelve weeks after surgery, weight was maintained and physical quality of life was better in the intervention group than the non-intervention group (P=0.03).

Conclusions

The intervention led to significant weight loss and improved cardiometabolic markers. A larger, randomized controlled trial is needed to evaluate efficacy and cancer biomarkers.

Funding

The Prostate Cancer Guys Resilient by Individualized Training (PCaGRIT) trial was supported the University of Kansas Cancer Center Cancer Prevention Pilot Grant program (JHR), and in part by an NIH Clinical and Translational Science Award grant (UL1 TR000001, formerly UL1RR033179), awarded to the University of Kansas Medical Center. Support for J. Hamilton-Reeves was provided by KL2 training grant KL2TR000119 a CTSA grant from NCATS awarded to the University of Kansas Medical Center for Frontiers: The Heartland Institute for Clinical and Translational Research (JHR). The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH or NCATS. Research reported in this publication was supported by the National Cancer Institute Cancer Center Support Grant P30 CA168524 and used the Biospecimen Shared Resource and the Biostatistics and Informatics Shared Resource. Medifast donated the meal replacements for the study.